| Field | Specification |
|---|---|
| Target | |
| Alternative names | Inhibitor of nuclear factor kappa-B kinase subunit beta;I-kappa-B-kinase beta;IKK-B;IKK-beta;IkBKB;2.7.11.10;I-kappa-B kinase 2;IKK2;Nuclear factor NF-kappa-B inhibitor kinase beta;NFKBIKB;IKBKB;IKKB; |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human IKK beta recombinant protein (Position: E398-S756). Human IKK beta shares 91% and 90% amino acid (aa) sequences identity with mouse and rat IKK beta, respectively. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody detects inhibitor of nuclear factor kappa-B kinase subunit beta (gene IKBKB) in human samples and is validated for flow cytometry, ICC/IF, IHC and Western blot. The predicted molecular weight is 86.6 kDa, and the supplier reports an observed band at about 43 kDa.
IKKβ (IKBKB) is the main catalytic subunit of the IKK complex in the canonical NF-κB pathway. In response to cytokines, microbial products and stress, it phosphorylates IκB proteins, targeting them for proteasomal degradation and releasing NF-κB to enter the nucleus, so it is a central kinase in inflammation research.
| Target | Inhibitor of nuclear factor kappa-B kinase subunit beta (gene IKBKB; UniProt O14920, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human |
| Form | Lyophilized |
| Formulation | Per vial: 0.9 mg NaCl; 0.2 mg Na2HPO4; 0.05 mg NaN3; plus stabilizers |
| Calculated MW | 86.6 kDa |
| Observed MW | 43 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.5 µg/mL (Human) |
|---|---|
| IHC (paraffin sections) | 0.5–1 µg/mL (Human) |
| Immunocytochemistry / Immunofluorescence | 2 µg/mL (Human) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
Samples with a confirmed band (WB): HepG2 cells, COLO320 cells, MDA-MB-231 cells, HT1080 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Samples with confirmed staining (IHC): human lung cancer tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Samples with confirmed staining (ICC/IF): A431 cells.
Samples with a confirmed signal (flow cytometry): 293T cells.
Immunogen
Recombinant human IKK beta fragment (Glu398–Ser756), expressed in E. coli. Sequence identity with the mouse and rat orthologs: 91% and 90%, respectively.
Reactivity Notes
The supplier lists reactivity with human. UniProt places inhibitor of nuclear factor kappa-B kinase subunit beta in the cytoplasm, nucleus and membrane raft. Tissue expression noted by UniProt (human): Highly expressed in heart, placenta, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis and peripheral blood. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
Yufang Lu et al. (2025) Baicalin ameliorates neuroinflammation by targeting TLR4/MD2 complex on microglia via PI3K/AKT/NF-κB signaling pathway. Neuropharmacology. 10.1016/j.neuropharm.2025.110296
